Vinge has advised Xspray Pharma, a pharmaceutical company with several product candidates in clinical development listed on Nasdaq Stockholm, in connection with a share issue whereby the company raises proceeds of SEK 100 million.
A bid consortium, acting through IR Holding Bidco Inc, has announced and completed a public offer to the shareholders of IRRAS AB (publ). The consortium included, among others, IRRAS’ two largest shareholders, Spetses Investments Ltd and Bacara Holdings Limited, both advised by Vinge.
SAGA Diagnostics AB, a cancer diagnostics and disease monitoring company, has carried out a convertible note issue of approximately SEK 144 million. Vinge advised SAGA Diagnostics in connection with the transaction.
Vinge has advised Repligen Corporation and subsidiaries ("Repligen"), a multinational life sciences group that develops and commercializes highly innovative bioprocess technologies and systems that enable efficiency in the biopharmaceutical manufacturing process, in connection with its acquisition of Metenova Holding AB with subsidiaries (“Metenova”).